Aemetis, Inc. (NASDAQ:AMTX) Receives $12.95 Average PT from Analysts

Aemetis, Inc. (NASDAQ:AMTX) has received an average recommendation of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $12.95.

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Aemetis in a research note on Monday, December 23rd. StockNews.com raised Aemetis to a “sell” rating in a research note on Friday, January 3rd.

Aemetis Stock Performance

Aemetis stock opened at $2.82 on Monday. The company has a market cap of $140.25 million, a P/E ratio of -1.25 and a beta of 1.47. Aemetis has a one year low of $2.10 and a one year high of $7.03. The business has a fifty day moving average of $3.28 and a two-hundred day moving average of $2.97.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. The firm had revenue of $81.44 million for the quarter, compared to analyst estimates of $77.79 million. During the same period last year, the firm earned ($0.59) EPS. Sell-side analysts predict that Aemetis will post -2.02 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in Aemetis by 68.2% in the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock valued at $52,000 after purchasing an additional 9,137 shares during the last quarter. Hutchinson Capital Management CA purchased a new stake in Aemetis in the 2nd quarter valued at about $70,000. Barclays PLC grew its holdings in Aemetis by 274.6% in the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock valued at $109,000 after buying an additional 34,816 shares during the period. Rhumbline Advisers grew its holdings in Aemetis by 2,837.1% in the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Aemetis in the 3rd quarter valued at about $177,000. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.